Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.

Abstract

(188)Re-HEDP is an effective radiopharmaceutical used in the palliative treatment of metastatic bone pain. The radiation-absorbed dose is acceptable for bone pain palliation with low doses for the normal bone marrow and the whole body.